paxalisib · NCT05183204 registry update

status: SUSPENDED → COMPLETED; primary_completion: 2026-06 → 2026-08-10; completion: 2026-06 → 2026-08-10; enrollment: 33 → 24; why_stopped: Pending results of interim analysis →

Key facts

Filed: Sep 25, 2026, 03:20 PM
Event: Trial registry change
Direction: Neutral
Company: KZIAKazia Therapeutics
Asset: paxalisib
Source: ClinicalTrials.gov
Confidence: Sourced

More on this asset

Sep 28, 2026

03:22 PM

KZIAKazia Therapeutics

paxalisib · NCT03994796 registry update

Trial registry changeClinicalTrials.gov

Sep 22, 2026

07:30 PM

KZIAKazia Therapeutics

Kazia Therapeutics: Sovargen doses first patient in Phase 1b/2a trial of paxalisib in FCD T2 and TSC

Trial registry changeCompany press release